MX2021005029A - Anticuerpos monoclonales antirabicos y combinados de los mismos. - Google Patents
Anticuerpos monoclonales antirabicos y combinados de los mismos.Info
- Publication number
- MX2021005029A MX2021005029A MX2021005029A MX2021005029A MX2021005029A MX 2021005029 A MX2021005029 A MX 2021005029A MX 2021005029 A MX2021005029 A MX 2021005029A MX 2021005029 A MX2021005029 A MX 2021005029A MX 2021005029 A MX2021005029 A MX 2021005029A
- Authority
- MX
- Mexico
- Prior art keywords
- rabies
- cocktail
- monoclonal antibodies
- disclosure provides
- monoclonal antibody
- Prior art date
Links
- 206010037742 Rabies Diseases 0.000 title abstract 5
- 241000700605 Viruses Species 0.000 abstract 3
- 230000002064 post-exposure prophylaxis Effects 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000282421 Canidae Species 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 abstract 1
- 241000288673 Chiroptera Species 0.000 abstract 1
- 241000282375 Herpestidae Species 0.000 abstract 1
- 241000266847 Mephitidae Species 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 229960003127 rabies vaccine Drugs 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona un anticuerpo monoclonal murino capaz de unirse a virus de rabia o virus relacionados y neutralizarlos. También proporciona un combinado (cocktail) de al menos dos anticuerpos monoclonales con la capacidad de unirse a los virus de rabia o virus relacionados y neutralizarlos. Según la presente invención, dicho combinado puede neutralizar los virus de rabia o virus relacionados que se derivan de especies como murciélagos, perros, vacas, mangostas, zorrillos y lobos, en consecuencia, pueden ser útiles para tratar a un paciente que posiblemente haya sido infectado por virus de rabia o virus relacionados derivados de una amplia variedad de especies. Por otra parte, la presente invención proporciona la combinación de anticuerpos monoclonales murinos o el combinado de al menos dos anticuerpos monoclonales y vacuna antirrábica para su uso en profilaxis postexposición (PEP, por sus siglas en inglés) con virus de rabia o virus relacionados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201821041598 | 2018-11-02 | ||
| PCT/IB2019/059118 WO2020089742A1 (en) | 2018-11-02 | 2019-10-24 | Anti-rabies monoclonal antibodies and cocktail thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021005029A true MX2021005029A (es) | 2021-07-15 |
Family
ID=68655573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021005029A MX2021005029A (es) | 2018-11-02 | 2019-10-24 | Anticuerpos monoclonales antirabicos y combinados de los mismos. |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3873526B1 (es) |
| CN (1) | CN113226372A (es) |
| BR (1) | BR112021008240A2 (es) |
| EC (1) | ECSP21039816A (es) |
| MA (1) | MA54075A (es) |
| MX (1) | MX2021005029A (es) |
| PE (1) | PE20211056A1 (es) |
| PH (1) | PH12021550987A1 (es) |
| WO (1) | WO2020089742A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013048130A2 (ko) | 2011-09-30 | 2013-04-04 | (주)셀트리온 | 광견병 바이러스를 중화시킬 수 있는 결합 분자 |
| EP3220947B1 (en) * | 2014-11-18 | 2020-10-28 | Humabs Biomed S.A. | Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof |
| WO2017027805A1 (en) * | 2015-08-13 | 2017-02-16 | University Of Massachusetts | Human antibodies against rabies and uses thereof |
-
2019
- 2019-10-24 CN CN201980086084.6A patent/CN113226372A/zh active Pending
- 2019-10-24 MX MX2021005029A patent/MX2021005029A/es unknown
- 2019-10-24 BR BR112021008240-9A patent/BR112021008240A2/pt unknown
- 2019-10-24 MA MA054075A patent/MA54075A/fr unknown
- 2019-10-24 WO PCT/IB2019/059118 patent/WO2020089742A1/en unknown
- 2019-10-24 PE PE2021000646A patent/PE20211056A1/es unknown
- 2019-10-24 EP EP19809146.4A patent/EP3873526B1/en active Active
-
2021
- 2021-04-30 PH PH12021550987A patent/PH12021550987A1/en unknown
- 2021-06-02 EC ECSENADI202139816A patent/ECSP21039816A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021008240A2 (pt) | 2021-10-26 |
| ECSP21039816A (es) | 2021-09-30 |
| MA54075A (fr) | 2022-02-09 |
| EP3873526B1 (en) | 2024-09-04 |
| PH12021550987A1 (en) | 2021-11-08 |
| EP3873526A1 (en) | 2021-09-08 |
| WO2020089742A1 (en) | 2020-05-07 |
| CN113226372A (zh) | 2021-08-06 |
| PE20211056A1 (es) | 2021-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502673A1 (en) | Anti-zika virus antibodies and methods of use | |
| MX2024006462A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| PH12020550145A1 (en) | Chemical Compounds | |
| MX2021015687A (es) | Anticuerpos humanos contra glicoproteina del virus ebola. | |
| MX2018003282A (es) | Anticuerpos neutralizantes de poliomavirus. | |
| SG10201806025TA (en) | Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen | |
| PH12020550025A1 (en) | Multispecific antibodies specifically binding to zika virus epitopes and uses thereof | |
| PH12015502164A1 (en) | Flavivirus neutralizing antibodies and methods of use thereof | |
| MX2018006416A (es) | Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina. | |
| PH12018501154A1 (en) | Attenuated infectious bronchitis virus | |
| CL2022002412A1 (es) | Vacuna | |
| MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| WO2020106358A8 (en) | Novel anti-zika virus antibodies and uses thereof | |
| MX2022008809A (es) | Virus de vacuna del sindrome respiratorio y reproductivo porcino. | |
| MX2021012695A (es) | Vacuna de subunidad del virus de la fiebre porcina clasica (csfv). | |
| IL290923A (en) | Antibody preparations and methods for treating hepatitis b virus infection | |
| WO2018066999A3 (en) | Chimeric enterovirus virus-like particles | |
| PH12020551051A1 (en) | Human antibodies to influenza hemagglutinin | |
| MX2021004356A (es) | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. | |
| PH12021550987A1 (en) | Anti-rabies monoclonal antibodies and cocktail thereof | |
| WO2019209974A3 (en) | Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination | |
| MX2019002696A (es) | Metodos para tratar o prevenir una infeccion del virus del zika. | |
| MX2023009447A (es) | Anticuerpos que se unen a metapneumovirus, proteínas antigénicas de metapneumovirus, y usos de los mismos. | |
| EA202091829A1 (ru) | Конструкты антител на основе нуклеиновой кислоты для использования против респираторного синцитиального вируса |